In this paper, we will summarize relevant knowledge and methods for analysis on ABC transporters which may be useful for the further study of ABCC6.

Pseudoxanthoma elasticum is an autosomal recessive disorder resulting from aberrant mineralization and fragmentation of elastic fibers in the extracellular matrix of the skin, the eyes and the cardiovascular system. It is characterized by papular skin lesions, a retinopathy prone to hemorrhage due to subretinal neovascularisation, and premature occlusive vessel disease, with considerable inter- and intra-familial variability of severity ([@B58]). Thirteen years after the discovery of the causal relation between *ABCC6* mutations and PXE, significant progress has been made in the characterization of the *ABCC6* gene and the transporter it encodes ([@B5]; [@B36]). Nevertheless, ABCC6 remains surrounded by a number of unsolved enigmas, including its substrates and physiological functions as well as the mechanisms by which it is connected to ectopic elastic fiber mineralization. Further, the significant variability in clinical severity of the PXE phenotype cannot be explained by the *ABCC6* mutations, as demonstrated by numerous negative genotype-phenotype correlation studies ([@B43]; [@B19]; [@B13]; [@B51]). This suggested the involvement of modifier genes, influencing particularly the severity of PXE symptoms ([@B62]).

Despite marked structural resemblance with other ABC transporters, ABCC6 has been considered the odd man out, due to its unique relation with a connective tissue disease affecting tissues in which it is hardly expressed. Drawing analogies between ABCC6 and the other ABC transporters has been done in the past, particularly to gain insights in substrate interactions. While, after more than a decade, the identification of this substrate is being further pursued, it may be a good time to evaluate if information on other ABC transporters as well as the difficulties that were and are still encountered in their study may point out potential pitfalls, concepts and approaches on how to deal with the challenges in the field of PXE.

THE PHYSIOLOGICAL FUNCTIONS OF ABCC6
====================================

Perhaps one of the most intriguing questions surrounding ABCC6 is the nature of its substrate and hence the physiological function of the transporter. Following unsuccessful comparisons, it is doubtful that the function of other members of the ABC transporter family will imply anything concerning the actual function of ABCC6 ([@B39]). It has been previously demonstrated in plant ABC transporters that -- despite phylogenetic similarities and domain homologies -- related ABC transporters can in fact serve diverse physiological functions. In humans, this was endorsed through the comparison of the cystic fibrosis transmembrane conductance regulator (ABCC7 or CFTR, the gene for cystic fibrosis) and P-glycoprotein (ABCB1 or MDR -- multidrug resistance protein; [@B38]). This however does not imply that nothing can be learned from previous experiences with functional dissection of ABC transporters. Awareness has risen for several of these that the complexity of (patho)physiological mechanisms related to the wild type and mutant transporter is much higher than anticipated; in this respect and based on our current knowledge, ABCC6 will probably not be an exception to the rule. This enlarging complexity began with the changing concept of substrate specificity. For several ABC transporters either one or a small number of closely related substrates are known. However, there have been reports of other transporters, such as ABCC1, ABCC2 or ABCB1, for which multispecificity for a diverse range of substrates has been shown ([@B29]; [@B23]). The diversity of (patho)physiological observations in PXE -- oxidative stress, the PXE serum factor, vitamin K deficiency, the relation with *ENPP1*, does not make it unthinkable that they result from aberrant transport of more then one substrate, thus influencing more than one physiological process ([@B35]; [@B49]; [@B59]; [@B47]). For many ABC transporters -- including ABCC6 -- the specific sequences responsible for substrate recognition have not yet been identified, which may add to the complexity of substrate identification ([@B20]). Nevertheless, for some transporters such as ABCC2 and Pgp, binding-site models have been proposed usingrelatively high accuracy *in silico* methods. Such models include the presence of one large binding site and multiple smaller ones, primary and secondary binding sites or three distinct sites ([@B26]; [@B8]; [@B50]; [@B18]).

These *in silico* approaches such as molecular docking, though insufficiently reliable to pinpoint with certainty the physiological substrates, may also have the advantage to generate a list of potential substrates in a cost- and time-efficient manner. Subsequently, these predictions need to be validated *in vivo*. Several approaches can be applied to identify physiological compounds transported by ABC proteins, such as *in vivo* hepatobiliairy elimination studies in mutant animal models, and using membrane vesicles or functional assays based on mass spectrometry ([@B14]; [@B31]; [@B29]). Though murine model organisms are commonly used for such experiments and the *Abcc6*knock-out mouse model largely recapitulates the clinical features of PXE, there have been reports emphasizing the differences in the physiological mechanisms between rodents and humans, which may slow down substrate identification ([@B28]). This has been the case for the ABCG2 protein, recently discovered to be an urate transporter ([@B46]). It should remind us to be cautious to extrapolate findings (positive or negative) in other species to the human disease. Remembering the adage that humans remain the most optimal model to search for substrate(s), an interesting approach for substrate screening has been reported for ABCC2 ([@B33]). To determine the extent of its substrate spectrum, a variant on the classic vesicular transport experiments has been applied to extract substrates from body fluids. Classic vesicular transport studies have as a drawback that an upfront hypothesis about the transported compounds is necessary and that only one substrate can be evaluated at a time. Certainly, the necessity of an upfront hypothesis is a major disadvantage with respect to ABCC6. By incubating the vesicles in body fluids (in the case of *Abcc2* murine urine) and analyzing the vesicle content by LC/MS, several novel compounds were identified. To apply this technique for ABCC6 would imply the use of human plasma and/or hepatocytes. This transportomics technique has great potential with several advantages including a reduced number of experimental animals and would mean that identification of compounds is not a prerequisite to study their transport in vesicular transport experiments as one can fish for new substrates. Combining transportomics with untargeted metabolomics analysis would further increasethe range of potential substrates that can be identified. Disadvantages of the technique include that it is less suitable for identifying hydrophobic substrates. The complex composition of body fluids may require. fractionation to limit the effect of regulators of the transporter which could mask transport of some substrates ([@B33]).

After several years of tranquility, the expression profile of *ABCC6* has again been the subject of debate. ABCC6 is predominantly expressed at the basolateral side of liver and kidney cells, though the transporter also has differential expression in the gut and gastro-intestinal tract ([@B55]; [@B44]; [@B52]). Recently, a supposed intracellular location in the mitochondria-associated membrane (MEM) -- part of the ER complex -- has been described ([@B40]). Though the shift in the paradigm linking the expression and function of ABCC6 to the hepatic and renal plasma membrane (PM), which is declared in this paper, should be reviewed with skepticism -- the amount of evidence locating ABCC6 in the PM is after all overwhelming -- the concept of an additional intracellular localization is potentially interesting and may further increase the complexity of the pathophysiological enigma at hand. This issue has been the topic of debate in recent papers by respectively [@B40], [@B41] and [@B52]. Demonstrating again the PM localization of ABCC6, the latter group could not confirm the MEM localization while the former called on methodological arguments to defend their findings ([@B41]; [@B52]). Challenging the cellular localization of proteins is not unprecedented in the ABC superfamily. Recently, the position of the ABCB6 transporter, originally thought to function in mitochondrial porphyrin metabolism, was challenged and extensively documented with experimental and literature data ([@B32]). Despite the critical review and convincing evidence of the true physiological function of ABCB6, the authors did not completely exclude a contribution of ABCB6 to porphyrin metabolism and appealed for further and thorough study of the true pathophysiological function(s) of this transporter ([@B32]). The knowledge on the subcellular localization of a native protein is of critical importance to model and understand the pathophysiology of any disease. Therefore, unity should be achieved regarding the PM localization of the ABCC6 transporter, but as with ABCB6 I would at this point not completely reject the idea of an additional intracellular localization of ABCC6. In view of the current contradictory results on the potential MEM localization, further work should be done to clarify this issue as the abnormal mitochondrial morphology and membrane potential in PXE -- mentioned by [@B40] as supporting evidence is insufficient; indeed, it has been demonstrated for the renal ABCB1 transporter that morphological abnormalities of the mitochondria can occur in the absence of a mitochondrial localization, possibly due to accumulation of toxic products ([@B27]). It cannot be excluded that ABCC6 may move between different membrane compartments under particular conditions, which theoretically may explain the contradicting findings for MEM localization. This has been shown for the PM ABCA1 transporter which, in the absence of extracellular Apo-AI, can be sequestered on intracellular membranes or degraded ([@B56]). As one particular protein can serve strictly different functions in separate parts of the same cell -- in view of the complexity of what we know on PXE, this might not even be so unexpected -- a validated intracellular localization of ABCC6 may help us further to understand the disease ([@B34]).

Though much attention has been paid to the expression of the ABCC6 transporter in the liver, its presence in the kidney, gut and the intestinal tract are less frequently the focus of attention. It has been shown for ABC transporters such as ABCC2 that the ABC protein may have different organ-specific functions ([@B29]). Where in the liver it functions in biliairy transport, in the kidney it is involved in the excretion of small organic anions. A similar tissue-dependent function was shown for ABCA1 and ABCG1 ([@B57]). Specifically addressing these extra-hepatic ABCC6 proteins is necessary as it is not unconceivable that for example the mucosal involvement in PXE may depend on or be modulated by the intestinal ABCC6 transporter.

REGULATION OF ABCC6
===================

Distinct pathways are involved in the regulation of ABC transporters, comprising genetic, epigenetic and nuclear-receptor mediated mechanisms, as well as post-transcriptional target repression by microRNAs (miRNAs), which can be triggered by hormones, growth factors and exogenous factors. Several examples exist of ABC transporters, such as Pgp, MRP4, BCRP, whose regulation depends on a combination of mechanisms ([@B42]). Nuclear factor regulation and methylation dependent epigenetic regulation has been described for ABCC6 ([@B3]; [@B15]; [@B53]). So far, no correlation with the PXE phenotype, its variability or potential therapeutic approaches has been attempted. The influence of epigenetic changes, such as promotor DNA methylation, on disease variability has been shown for ABCA1 and coronary artery disease and various drug transporters such as ABCB1and MDR1 ([@B4]; [@B54]; [@B21]). Therapeutic consequences may include the use of histone deacytelase inhibitors, as reported for MDR1 ([@B30]).

MicroRNA is a family of short non-coding RNAs involved in the negative regulation of gene expression at the posttranscriptional level ([@B22]). With a few hundred miRNAs identified, it is estimated that 50% of the protein-coding genes are regulated by them. Among ABC transporters, miRNA dependent regulation has been documented for *CFTR*, *MRP2* and *4*, *PgP* and *BCRP*, either directly or indirectly through nuclear factors ([@B7]; [@B48]). In the *CFTR*gene, variants have been described that may influence the miRNA target sites in the 3′ UTR ([@B2]). It has been suggested that certain single nucleotide polymorphisms (SNPs) can influence the affinity for inhibitory miRNAs and may explain the differences in clinical expression between patients with an identical genotype. Mutations in the 3′ UTR have also been described in the *ABCC6* gene, so the involvement of miRNAs in PXE pathophysiology may not be purely theoretical. Identification of such miRNAs does not only open the possibility of using modulators, such as chemically engineered oligonucleotides called antagomirs, with the goal of influencing mechanisms that underlie disease initiation or progression ([@B42]). Of interest is that miRNAs have been demonstrated useful biomarkers in kidney disease ([@B2]; [@B16]). The development of an accurate biomarker set for PXE, which does not yet exist, will enable clinical studies to determine whether a compound has a clinically significant effect on the PXE phenotype.

CLINICAL VARIABILITY
====================

The clinical variability of the PXE phenotype remains a challenge for patients and physicians, making an individualized approach at this moment nearly impossible. Because of the lack of correlations between the patients phenotype and *ABCC6* genotype, the possibility of modifier genes has been suggested ([@B24]; [@B63], [@B62]). The number of potential modifier genes in PXE is currently still limited, which is not totally unexpected; for many ABC transporters the identification of clinical modulators remains challenging. The clinical variability in PXE shows similarities with the variability in cystic fibrosis (CF), the clinical course of which is also difficult to predict using the *ABCC7* mutations. Consequently, the quest for modifier genes has started and several modifiers of pulmonary outcome in CF have been described ([@B6]; [@B9]; [@B61]; [@B60]). The search for CF modifiers has lead to several recommendations which are equally valid for ABCC6. First, the importance of an in depth, unambiguous and universal definition of the phenotype has been deemed extremely important. Indeed, the description of the clinical features of the PXE phenotype is often inconsistent in different reports, even when tools such as the Phenodex^®^ are available ([@B51]). A more standardized definition of the phenotypic features will allow a more reliable identification and comparison of modifiers. Further, the limitations of association studies where the relationship between phenotype and polymorphisms in candidate modifier genes is examined have become clear, with the possibility of false positive studies or the causal effect of other genes which may travel with the candidate gene(s) ([@B45]; [@B1]). Finally, a study in twins and siblings in CF indicates that functions directly related to CFTR, membrane ion transport and/or intracellular trafficking of mutant protein are subject to modifier effects ([@B11], [@B10]). Identification of modifiers for functions directly related to the ABC transporter may also yield further insights in the pathophysiology of PXE and provide novel therapeutic targets. Next generation sequencing (NGS), a revolutionizing sequencing technique enabling parallel sequencing of multiple genes and whole exome sequencing is also an opportunity to identify modifier genes and variants, particularly in rare disorders in which large cohorts are often difficult to gather. By combining analysis of extreme phenotypes with pathway analysis, significant power can still be obtained, as was demonstrated by using NGS in CF ([@B17]).

Modifier genes may not be the only mechanism involved in the variability of PXE. For several ABC transporters, compensatory mechanisms have been described. These include upregulation of MRP3 expression in Dubin-Johnson syndrome, thus compensating for the impaired ABCC2 function ([@B42]). Such compensatory mechanisms have also been suggested for PXE. Gene expression profiling of ABC transporters in dermal fibroblasts revealed increased expression of seven genes, including *ABCC2* and several members of the A-subfamily ([@B25]). The latter was further explored in hepatocytes of a knock-out mouse model where tissue specific upregulation of *Abca4* was demonstrated in the liver ([@B37]). However, no further studies have investigated other potential compensatory mechanisms, though they may be of significant importance in understanding PXE, for aiming a more personalized follow-up of patients and for the introduction of novel therapeutic approaches.

AN INTEGRATIVE APPROACH FOR PXE RESEARCH
========================================

Pseudoxanthoma elasticum is one of the diseases where, through the dedicated work of a relatively small group of researchers, a large number of data and observations are gathered. To take on the challenges that we are facing in the field of PXE, integration of all these data and findings may ultimately be the most difficult though imperative step to move forward efficiently. One interesting initiative in this respect is the Clinical and Functional Translation of CFTR (CFTR2) project, which presents a novel approach to clinical and functional annotation of mutations in the *CFTR* gene. Within this project, clinical and molecular data are gathered from CF registries and centers, in a standardized way and under the control of data managers. Further, data on functional assessment of mutations was added ([@B12]). Though valuable initiatives have been taken to establish mutation database for *ABCC6*, and linking these molecular data to phenotypical characteristics, no such comprehensive database is currently available. A comprehensive database would improve our ability to identify biomarkers and interpret underlying mechanisms of disease variability in PXE. This database would ideally incorporate information on functional mutation data, potential or established modifier variants, exome sequencing data, serum measurements of patients, fibroblast observations, proteomics, metabolomics and other -omics in clinically well-characterized patients. This is expected to enhance diagnostics, carrier testing and screening, genotype-phenotype correlations, modifier analysis and insights into pathogenesis and therapies. It can be concluded that the other members of the ABC transporter family can provide us with valuable information and useful precedents for further characterizing the ABCC6 transporter. Perhaps the most important lesson to incorporate in current PXE research is the concept that only an integrative approach will finally enable us to elucidate this disease completely. To this purpose, it is therefore imperative that joint initiatives can be outlined to merge and integrate past, present and future research data.
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